Topic summary

EMA product information as a primary source

Regional › European Union personal import formulary EMA

This is a generated summary. It shows the 9 most-liked posts from a topic of 75, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

in.guerreroTL2 Moderator29 Oct 2025 · edited#13

h.nicolaides, post #12: I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient. Go to post

On post #9 — agreed on the reasoning, with one qualification.

Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.

25 likes in reply to #12 9mo

s.cardosoTL2 Moderator2 Nov 2025#23

b.solberg, post #8: I read post #6 twice before replying, because I had assumed the opposite. Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available. Go to post

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

30 likes in reply to #8 9mo

ka.haddadTL2 Moderator3 Nov 2025#27

m.coelho, post #7: Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents. Go to post

post #26 is right about the mechanism and I think understates the practical bit.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

22 likes in reply to #7 9mo

h.castellanosTL2 Moderator7 Nov 2025#40

crossover_entry, post #9: post #8 answers the question as asked. The question underneath it is different. Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation. Go to post

Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.

22 likes in reply to #9 9mo

diluent_indexTL1Member8 Nov 2025#43

25 likes 9mo

n.stanescuTL2 Moderator10 Nov 2025#53

in.guerrero, post #13: On post #9 — agreed on the reasoning, with one qualification. Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it. Go to post

Worth separating two things that post #49 runs together.

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

23 likes in reply to #13 9mo

c.vermeulenTL2 Moderator12 Nov 2025#57

citation_peak, post #20: Picking up post #17: that is the part I would want checked first. Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common. Go to post

On post #53 — agreed on the reasoning, with one qualification.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

31 likes in reply to #20 8mo

preregisteredTL3Research methods12 Nov 2025#60

This follows post #57 rather than contradicting it.

24 likes 8mo

crossref_checkTL3Wiki editor13 Nov 2025#64

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

33 likes 8mo

Read the full topic (75 posts)

This topic was referenced in

Coming back to: Cross-border purchase rules within the EURegional › European Union · 16 replies
EU-wide position versus national implementation — what changed sinceRegional › European Union · 26 replies

Promoted into the documentation commons. The content of this topic is maintained at Access notes: France, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
German, French and Dutch differences, compared Regional › European Union cost per milligram formulary EMA German, French and Dutch differences, compared — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…		2	12k	10h
EMA product information as a primary source — does this still hold? Regional › European Union EMA cost per milligram formulary personal import Solved Closed The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…	+127	150	41k	20mo
Second pass at: Reimbursement variation across member states Regional › European Union personal import formulary cost per milligram EMA On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…	+23	28	45k	21mo
Coming back to: Cross-border purchase rules within the EU Regional › European Union EMA cost per milligram personal import Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…	+12	16	2.8k	11mo
EU-wide position versus national implementation Regional › European Union EMA personal import cost per milligram formulary Solved Under review EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…	+22	29	356	11mo

Related topics — sharing the tags personal import, formulary, EMA

Topic	Participants	Replies	Views	Activity
[2026 update] An appeal that failed, and what I would do differently Access › Insurance & coverage prior authorisation insurance formulary Posting this under the heading it deserves: An appeal that failed, and what I would do differently Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…	+152	159	2.5k	13mo
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…	+36	40	37k	11mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…	+87	94	1.1k	21d
Reading a regulatory notice rather than an article about it Sourcing › Regulatory compounding personal import EMA Posting this under the heading it deserves: Reading a regulatory notice rather than an article about it Everything below is what sits behind that. Structured report rather than an opinion, following the…		2	2.9k	5mo
[2026 update] EU-wide position versus national implementation Regional › European Union personal import cost per milligram formulary EMA Solved On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…		2	54k	19mo